RETA - Reata Pharmaceuticals Inc Stock Price, Fair Value and News

Market Closed

RETA Stock Price

View Fullscreen

RETA RSI Chart

RETA Valuation

Market Cap

6.5B

Price/Earnings (Trailing)

-74.1

Price/Sales (Trailing)

2.9K

EV/EBITDA

-75.3

Price/Free Cashflow

-26.03

RETA Price/Sales (Trailing)

RETA Profitability

EBT Margin

-3956.59%

Return on Equity

-100.38%

Return on Assets

-17.43%

Free Cashflow Yield

-3.84%

RETA Fundamentals

RETA Revenue

Rev. Growth (Yr)

2.9K%

Rev. Growth (Qtr)

100%

RETA Earnings

Earnings (TTM)

-87.6M

Earnings Growth (Yr)

362.39%

Earnings Growth (Qtr)

266.21%

Breaking Down RETA Revenue

Last 7 days

0.2%

Last 30 days

1.8%

Last 90 days

83.7%

Trailing 12 Months

526.6%

How does RETA drawdown profile look like?

RETA Financial Health

Current Ratio

3.21

Debt/Equity

0.84

Debt/Cashflow

-3.4

RETA Investor Care

Shares Dilution (1Y)

2.31%

Diluted EPS (TTM)

-2.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	11.5M	10.0M	3.1M	2.2M
2021	8.6M	7.8M	13.7M	11.5M
2020	20.1M	15.3M	8.5M	9.0M
2019	29.0M	29.2M	32.3M	26.5M
2018	67.7M	62.5M	55.1M	53.6M
2017	50.1M	50.6M	50.6M	48.1M
2016	49.8M	49.8M	49.9M	49.9M
2015	51.5M	51.1M	50.7M	50.3M
2014	0	0	0	52.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Reata Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 26, 2023	mcgaughy r kent jr	back to issuer	-	-	-280	-
Sep 26, 2023	huff james warren	back to issuer	-	-	-10,398	chief executive officer
Sep 26, 2023	mcgaughy r kent jr	back to issuer	-	-	-2,896,900	-
Sep 26, 2023	desai antal rohit	back to issuer	-	-	-11,076	-
Sep 26, 2023	desai antal rohit	back to issuer	-	-	-113	-
Sep 26, 2023	bir dawn carter	back to issuer	-	-	-33,805	chief commercial officer
Sep 26, 2023	desai antal rohit	back to issuer	-	-	-34,897	-
Sep 26, 2023	desai antal rohit	back to issuer	-	-	-282,246	-
Sep 26, 2023	desai antal rohit	back to issuer	-	-	-134	-
Sep 26, 2023	desai antal rohit	back to issuer	-	-	-334,740	-

Which funds bought or sold RETA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 13, 2024	PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO	sold off	-100	-1,612,000	-	-%
Jan 24, 2024	DekaBank Deutsche Girozentrale	sold off	-100	-2,930,000	-	-%
Jan 09, 2024	IFP Advisors, Inc	sold off	-100	-51,708	-	-%
Aug 10, 2023	Tekla Capital Management LLC	added	91.88	1,869,210	3,492,130	0.14%
Aug 10, 2023	PICTET ASSET MANAGEMENT SA	reduced	-17.42	-21,522	269,786	-%
May 15, 2023	Kula Investments, LLC	sold off	-100	-204,006	-	-%
Apr 14, 2023	STONNINGTON GROUP, LLC	new	-	969,701	969,701	0.25%
Feb 13, 2023	Gyon Technologies Capital Management, LP	sold off	-100	-388,000	-	-%
Nov 21, 2022	FourThought Financial, LLC	sold off	-100	-21,000	-	-%
Nov 14, 2022	EATON VANCE MANAGEMENT	reduced	-0.05	-83,000	393,000	-%

Are Funds Buying or Selling RETA?

Are funds buying RETA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RETA

No. of Funds

Unveiling Reata Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 28, 2023	biogen inc.	0.0%	0	SC 13D/A
Sep 28, 2023	cpmg inc	0.0%	0	SC 13D/A
Sep 26, 2023	rose william	0%	0	SC 13D/A
Sep 19, 2023	rose william	8.9%	3,182,950	SC 13D/A
Aug 24, 2023	rose william	9.1%	3,240,950	SC 13D/A
Aug 07, 2023	biogen inc.	23.4%	8,936,791	SC 13D
Aug 01, 2023	cpmg inc	13.2%	4,589,758	SC 13D/A
Jul 31, 2023	rose william	9.2%	3,240,950	SC 13D/A
Jun 26, 2023	adage capital partners gp, l.l.c.	5.24%	1,730,841	SC 13G
May 15, 2023	first light asset management, llc	3.91%	1,290,193	SC 13G/A

Reata Pharmaceuticals Inc News

Latest updates

Reata Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	100.0%	22,746,000	11,373,000	-	540,000	762,000	914,000	933,500	7,391,000	2,221,000	944,000	3,192,000	1,401,000	3,073,000	1,353,000	2,672,000	8,242,000	7,833,000	7,770,000	8,451,000	5,175,000	7,571,000
Operating Expenses	3.9%	114,949,000	110,650,000	79,523,000	71,027,000	64,747,000	64,953,000	72,502,000	65,486,000	62,351,000	55,858,000	57,173,000	55,786,000	53,667,000	68,718,000	187,103,000	46,820,000	41,492,000	36,322,000	33,373,000	34,735,000	34,223,000
S&GA Expenses	-16.8%	45,690,000	54,885,000	32,023,000	27,270,000	25,143,000	24,841,000	30,563,000	25,736,000	21,998,000	20,704,000	19,427,000	18,314,000	16,600,000	20,787,000	22,271,000	14,283,000	11,706,000	10,038,000	7,945,500	7,486,000	10,689,000
R&D Expenses	3.0%	57,120,000	55,477,000	47,223,000	43,485,000	39,331,000	39,804,000	41,616,500	39,430,000	40,066,000	34,880,000	37,460,500	37,183,000	36,783,000	47,653,000	40,161,500	32,279,000	29,554,000	26,114,000	25,308,500	27,144,000	23,429,000
EBITDA Margin	75.5%	-39.06	-159	-140	-98.54	-30.31	-26.44	-25.82	-20.18	-34.95	-30.26	-28.95	-44.77	-22.96	-16.00	-10.59	-3.72	-3.81	-3.69	-1.41	-1.22	-0.81
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	4,847,000	3,174,000	1,667,000	2,389,000	2,413,000	2,052,000	968,500	2,360,000	903,000
Income Taxes	-	-	-	-55,000	-	-1,000	31,000	218,500	-	-653,000	-15,000	-151,000	-93,000	-3,000	-22,240,000	-52,000	38,000	20,000	2,000	11,000	9,000	6,000
Earnings Before Taxes	266.2%	192,998,000	-116,117,000	-85,557,000	-79,002,000	-73,556,000	-73,811,000	-85,166,500	-71,846,000	-73,353,000	-67,470,000	-65,927,000	-65,549,000	-67,584,000	-71,179,000	-186,994,000	-39,656,000	-34,360,000	-29,152,000	-25,571,500	-30,826,000	-28,205,000
EBT Margin	75.2%	-39.57	-159	-140	-98.92	-30.44	-26.54	-25.92	-20.26	-35.10	-30.96	-29.96	-46.04	-23.82	-16.53	-10.94	-3.99	-4.10	-3.93	-1.50	-1.30	-0.85
Net Income	266.2%	192,998,000	-116,117,000	-85,502,000	-79,002,000	-73,555,000	-73,842,000	-85,385,000	-71,846,000	-72,700,000	-67,455,000	-65,776,000	-65,456,000	-67,581,000	-48,939,000	-186,942,000	-39,694,000	-34,380,000	-29,154,000	-25,582,000	-30,835,000	-28,211,000
Net Income Margin	75.3%	-39.54	-159	-140	-98.99	-30.46	-26.51	-25.88	-20.20	-34.98	-30.93	-27.47	-43.41	-22.37	-15.42	-10.94	-3.99	-4.10	-3.93	-1.50	-1.30	-0.85
Free Cashflow	14.0%	-70,202,000	-81,590,000	-50,793,000	-46,875,000	-51,396,000	-58,473,000	-123,125,000	-42,832,000	-25,869,000	-45,204,000	-45,528,000	-40,248,000	-196,233,000	-41,258,000	-149,628,000	-40,663,000	-33,641,000	-29,892,000	-37,806,000	3,040,000	-25,524,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	10.8%	503	454	514	584	632	680	735	732	778	815	858	613	652	664	682	259	300	331	345	382	175
Current Assets	20.8%	402	333	398	445	491	537	596	722	768	806	847	607	640	652	669	247	287	317	342	380	172
Cash Equivalents	-42.5%	49.00	85.00	42.00	32.00	147	532	590	713	756	778	818	578	610	624	664	240	280	313	338	375	139
Inventory	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	2.2%	11.00	11.00	11.00	11.00	11.00	11.00	12.00	7.00	6.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	1.00	1.00	1.00
Current Liabilities	129.1%	125	55.00	59.00	51.00	46.00	44.00	54.00	121	121	114	119	47.00	47.00	201	192	75.00	68.00	61.00	56.00	63.00	56.00
Long Term Debt	-	73.00	-	-	-	-	-	-	-	-	-	-	-	-	156	155	75.00	80.00	80.00	79.00	79.00	79.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	156	155	75.00	-	-	79.00	-	-
Shareholder's Equity	-	87.00	-	-	5.00	69.00	128	186	256	314	369	417	186	232	229	257	-	-	-	15.00	38.00	-
Retained Earnings	11.5%	-1,490	-1,683	-1,567	-1,482	-1,403	-1,329	-1,255	-1,170	-1,098	-1,025	-958	-892	-827	-759	-710	-523	-483	-449	-420	-394	-363
Additional Paid-In Capital	1.6%	1,578	1,553	1,502	1,487	1,472	1,457	1,442	1,426	1,412	1,395	1,376	1,078	1,059	988	967	456	450	445	435	432	196
Shares Outstanding	1.0%	37.00	37.00	37.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	34.00	33.00	33.00	33.00	30.00	30.00	30.00	30.00	28.00	29.00	26.00
Float	-	-	-	-	-	834	-	-	-	3,870	-	-	-	3,759	-	-	-	1,956	-	-	-	554

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	14.1%	-69,928	-81,449	-50,426	-46,534	-49,122	-58,185	-122,932	-42,158	-25,600	-45,011	-45,140	-40,093	-195,934	-41,173	-149,375	-40,335	-32,709	-28,732	-37,497	3,142	-25,407
Share Based Compensation	-46.5%	20,363	38,057	14,977	14,446	13,864	15,444	15,226	19,579	1,400	14,679	24,988	-	300	19,307	12,291	5,380	4,483	4,227	2,767	2,746	2,552
Cashflow From Investing	-138.7%	-42,946	110,995	60,506	-69,138	-336,244	-288	-193	-674	-269	-193	-388	-155	-299	-85.00	-253	-328	-932	-1,160	-309	-102	-117
Cashflow From Financing	486.9%	76,777	13,082	314	436	541	194	171	337	3,952	4,678	285,415	8,092	182,164	1,422	573,803	363	1,034	5,158	411	233,469	58,263

RETA Income Statement

2023-06-30

Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues
Total revenues	$ 22,746	$ 762	$ 22,941	$ 1,677
Operating cost and expenses
Cost of products sold	846	0	846	0
Research and development	57,120	39,331	112,597	79,136
Selling, general and administrative	45,690	25,143	100,575	49,984
Litigation settlement	11,000		11,000
Depreciation	293	273	581	581
Total operating cost and expenses	114,949	64,747	225,599	129,701
Other income (expense), net	285,201	(9,571)	279,539	(19,343)
Income (loss) from operations	192,998	(73,556)	76,881	(147,367)
Benefit from (provision for) taxes on income	0	1	0	(30)
Net income (loss)	$ 192,998	$ (73,555)	$ 76,881	$ (147,397)
Net income (loss) per share - basic	$ 5.12	$ (2.02)	$ 2.06	$ (4.04)
Net income (loss) per share - diluted	$ 4.65	$ (2.02)	$ 1.89	$ (4.04)
Weighted-average number of common shares used in net income (loss) per share - basic	37,671,678	36,467,802	37,311,872	36,440,364
Weighted-average number of common shares used in net income (loss) per share - diluted	41,506,900	36,467,802	40,758,929	36,440,364
Product revenues, net
Revenues
Total revenues	$ 20,038	$ 0	$ 20,038	$ 0
License and milestone
Revenues
Total revenues	0	754	0	1,648
Other revenue
Revenues
Total revenues	$ 2,708	$ 8	$ 2,903	$ 29

RETA Balance Sheet

2023-06-30

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 48,843	$ 42,312
Marketable debt securities	281,371	345,202
Accounts receivable, net	22,662	0
Prepaid expenses and other current assets	46,031	10,256
Inventory, current	2,942	0
Total current assets	401,849	397,770
Property and equipment, net	11,303	11,179
Operating lease right-of-use-assets	78,598	105,258
Inventory, noncurrent	10,338	0
Other assets	499	284
Total assets	502,587	514,491
Liabilities and stockholders' equity (deficit)
Accounts payable	19,860	18,706
Accrued direct research liabilities	25,135	13,836
Other current liabilities	71,991	24,267
Liability related to sale of future royalties, current	5,650	0
Operating lease liabilities, current	2,456	2,151
Total current liabilities	125,093	58,960
Opearting lease liabilities, noncurrent	90,417	117,313
Term Loan, net of debt issuance cost	73,130	0
Liability related to sale of future royalties, non-current	126,656	403,913
Total noncurrent liabilities	290,203	521,226
Commitments and contingencies
Stockholders' equity (deficit):
Additional paid-in capital	1,577,904	1,501,800
Accumulated deficit	(1,490,651)	(1,567,532)
Total stockholders' equity (deficit)	87,291	(65,695)
Total liabilities and stockholders' equity (deficit)	502,587	514,491
Common Stock A
Stockholders' equity (deficit):
Common stock value	33	32
Common Stock B
Stockholders' equity (deficit):
Common stock value	$ 5	$ 5

About Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

CEO	Mr. J. Warren Huff
WEBSITE	reatapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	321

Reata Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Reata Pharmaceuticals Inc? What does RETA stand for in stocks?

RETA is the stock ticker symbol of Reata Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Reata Pharmaceuticals Inc (RETA)?

As of Mon Sep 25 2023, market cap of Reata Pharmaceuticals Inc is 6.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RETA stock?

You can check RETA's fair value in chart for subscribers.

What is the fair value of RETA stock?

You can check RETA's fair value in chart for subscribers. The fair value of Reata Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Reata Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RETA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Reata Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RETA is over valued or under valued. Whether Reata Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Reata Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RETA.

What is Reata Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Sep 25 2023, RETA's PE ratio (Price to Earnings) is -74.1 and Price to Sales (PS) ratio is 2.93 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RETA PE ratio will change depending on the future growth rate expectations of investors.